Germany Decides On Added Benefit Of Gilead’s Veklury For COVID-19
The body in charge of pricing and reimbursement in Germany has downgraded the extent of additional benefit offered by Gilead’s Veklury for treating COVID-19 patients.
You may also be interested in...
The German pharmaceutical industry is calling for “directional correction” to the way implementation of the EU’s Health Technology Assessment Regulation is being developed.
Alnylam has opted to submit its orphan drug Amvuttra for a full benefit assessment in Germany, rather than an abbreviated process that requires no comparative data. In England, the drug was recommended following a pilot for designing a new and faster approach to health technology appraisals.
A Canadian court has dismissed an appeal brought by industry challenging new pricing rules that introduce a revised basket of reference countries as part of cost-containment measures.